Bridging the Gap: A Literature Review of Advancements in Obesity and Diabetes Mellitus Management

• Published in: Applied sciences Vol. 14; no. 15; p. 6565
• Main Authors: Pop, Gheorghe Nicusor, Manole, Felicia, Buleu, Florina, Motofelea, Alexandru Catalin, Bircea, Silviu, Popa, Daian, Motofelea, Nadica, Pirvu, Catalin Alexandru
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 01.08.2024
• Subjects: advanced glycation end products (AGEs); Antibodies; Autoimmunity; Behavior therapy; Biomarkers; Blood sugar; Body composition; Body fat; Body mass index; Care and treatment; Cognitive therapy; Development and progression; Diabetes; diabetes mellitus (DM); Diabetes therapy; diagnosis; Global health; Glycosylated hemoglobin; Insulin; Liraglutide; Literature reviews; Lorcaserin; Microbiota (Symbiotic organisms); Obesity; Overweight; Peptides; prescription digital therapeutics (PDTs); Prevention; Stem cells; Surgery; Transplantation; treatment; Type 2 diabetes; Viral antibodies; Weight control; Romania; United States > US
• ISSN: 2076-3417; 2076-3417
• DOI: 10.3390/app14156565

This literature review explores advancements in obesity and diabetes mellitus diagnosis and treatment, highlighting recent innovations that promise more personalized and effective healthcare interventions. For obesity diagnosis, traditional methods like body mass index (BMI) calculations are now complemented by bioelectrical impedance analysis (BIA) and dual-energy X-ray absorptiometry (DXA) scans, with emerging biomarkers from “omics” technologies. Diabetes diagnosis has advanced with standard hemoglobin A1c (HbA1c) testing supplemented by novel measures such as advanced glycation end products (AGEs) and autoantibodies, alongside the use of artificial intelligence to enhance diagnostic accuracy. Treatment options for obesity are expanding beyond traditional methods. Minimally invasive bariatric surgeries, endoscopic procedures, fecal microbiota transplants (FMTs), and pharmaceuticals like GLP-1 receptor agonists (semaglutide, tirzepatide) show promising results. Cognitive behavioral therapy (CBT) and prescription digital therapeutics (PDTs) are also valuable tools for weight management. Diabetes treatment is also undergoing a transformation. Ultra-long-acting insulins and innovative oral insulin delivery methods are on the horizon. SGLT2 inhibitors and GLP-1 receptor agonists are proving to be effective medications for blood sugar control. Continuous glucose monitoring (CGM) systems and closed-loop insulin delivery are revolutionizing diabetes management, while stem cell therapy holds promise for the future. By integrating advanced diagnostic tools with personalized treatment plans, obesity and diabetes care are entering a new era. This personalized approach empowers patients and paves the way for improved health outcomes and a better quality of life.